New value analysis of GlaxoSmithKline (GSK:LSE)

New value analysis of GlaxoSmithKline (GSK:LSE)

A new value analysis of GlaxoSmithKline, a  company listed in  London has been added to our research pages here.  GSK researches, develops and produces vaccines, medicines and consumer healthcare products.  GSK is a global company with headquarters in the UK.

GSK, recently showed up as cheap on earnings data and had a good dividend record so warranted further research.  However, GSK also looked expensive on price to book so some caution was also advisable.

The earnings picture was complicated by a deal done by GSK in 2015 with another drug company, Novartis.  The deal with Novartis has resulted in a big increase in earnings in 2015, but the last Annual Report for 2014 showed relatively low earnings.

There is a possible opportunity for value investors to purchase the common stock of GSK at a relatively low price.  To find out why GSK is possibly good value at current prices purchase the report here

OR

Click the button below to review options on becoming a member.

If you want to see a sample of the type of analysis you get from our report please click Apple Inc for a free sample.

[smlsubform prepend=”To receive updates when we add content to our website please use this form to register your e-mail”]